Background
death, toxicity, cancer, ESCC, Esophageal cancer
ESOPHAGEAL CANCER, MALIGNANT TUMOR, CANCER
Esophageal cancer (EC) is the seventh most common malignant tumor and the sixth leading cause of cancer-related mortality worldwide [Neoadjuvant therapy could increase the rate of R0 resection and improve survival compared with surgery alone [As a newcomer to cancer treatment, programmed cell death 1 (PD-1) blockade-based immunotherapy exploits a strategy based on immune evasion mechanisms to restore antitumor immunity. Camrelizumab is a humanized high-affinity IgG4-kappa anti-PD-1 monoclonal antibody that has demonstrated efficacy and safety in patients with advanced ESCC [To date, a few clinical trials have reported that neoadjuvant immunochemotherapy of PD-(L)1 blockade induced a favorable pathological response and tolerant toxicity in patients with locally advanced ESCC [In our previous retrospective study [